Aerovate Therapeutics Q1 net loss $16.5M; Phase 2b topline data pushed to Q2 2024

Jade Biosciences, Inc.

2023-Q1 EPS reported -$0.67

Topline Phase 2b data from IMPAHCT trial of AV-101 now expected in Q2 2024; >100 sites in 20 countries.
Cash, equivalents and short-term investments $118.9M at March 31, 2023; runway into H2 2025.
Net loss $16.5M for Q1 2023 vs $10.9M Q1 2022; R&D expenses $13.5M (up from $7.3M).
Enrollment pace increasing but slower than expected due to post-COVID factors.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Jade Biosciences, Inc. reported first quarter 2023 results: net income -$16.5 million.

Period: first quarter 2023
Net income: -$16.5 million
Result: reported results

Exact text from the filing

Net loss for the first quarter ended March 31, 2023 was $16.5 million as compared to $10.9 million for the first quarter ended March 31, 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Jade Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001798749-23-000037

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.